Many incurable diseases (e.g., cancer, neurodegeneration) involve biomolecules called ‘disordered proteins’. Considered ‘undruggable’ by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites with which drug-molecules can interact. Our mission is to make disordered proteins druggable. We will screen millions of disordered protein/drug-molecule pairs to learn the rules of drugging disordered proteins. Building on our expertise and working with academic and industrial partners, we will leverage cutting-edge biology, engineering, and AI to deliver new drugs and tools. To accomplish this in a manner for maximum societal benefit, we have established a Focused Research Organisation (FRO), a fully-independent not-for-profit entity dedicated to this goal.
| Website | https://www.bindresearch.org |
| Employees | 16 (6 on RocketReach) |
| Founded | 2024 |
| Industry | Biotechnology Research |
Looking for a particular Bind Research employee's phone or email?
Wendy Bushell is the Director of Operations of Bind Research.
6 people are employed at Bind Research.